| Dr Erick Franklin Huang, DO | |
|
3033 Campus Dr Ste W225, Plymouth, MN 55441-2752 | |
| (415) 429-6977 | |
| Not Available |
| Full Name | Dr Erick Franklin Huang |
|---|---|
| Gender | Male |
| Speciality | |
| Experience | Years |
| Location | 3033 Campus Dr Ste W225, Plymouth, Minnesota |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134388218 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Erick Franklin Huang, DO 3033 Campus Dr Ste W225, Plymouth, MN 55441-2752 Ph: (415) 429-6977 | Dr Erick Franklin Huang, DO 3033 Campus Dr Ste W225, Plymouth, MN 55441-2752 Ph: (415) 429-6977 |
News Archive
In recognition of Red Ribbon Week, October 23-31, 2012, Gateway Foundation Alcohol & Drug Treatment is working to build awareness among communities regarding the dangerous health risks associated with synthetic drug use.
Hearing impairment was more prevalent among men and older individuals in a study of U.S. Hispanic/Latino adults, according to a report published online by JAMA Otolaryngology-Head and Neck Surgery.
Seres Health, a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on scientific findings related to the human microbiome, announced today that it has closed its $10 million Series B financing that included existing investors Flagship Ventures and Enso Ventures, and included new investors, Mayo Clinic, Alexandria Venture Investments, and several private investors. The company has also entered into an exclusive research collaboration with the Mayo Clinic.
Alder Biopharmaceuticals Inc. today announced that patients with late-stage non-small cell lung cancer (NSCLC) showed improvement in cancer-related anemia and symptoms of the disease in a Phase 2a clinical trial of ALD518, a monoclonal antibody directed against interleukin-6 (IL-6).
4SC AG, a drug discovery and development company, today announced that the first patient has been dosed in the Phase I/II SHORE study with the oral pan-histone deacetylase (HDAC) inhibitor resminostat as a second-line treatment for patients with advanced and metastatic colorectal KRAS-mutant cancer.
› Verified 1 days ago
Erica N. Roberson, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 15700 37th Ave N, #300, Plymouth, MN 55446 Phone: 612-871-1145 Fax: 612-870-5491 | |
Dr. Thomas John Kaminsky, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 15700 37th Ave N Ste 300, Plymouth, MN 55446 Phone: 612-871-1145 Fax: 612-870-5491 | |
Alfred P. Chiang, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2700 Campus Dr, Suite 100, Plymouth, MN 55441 Phone: 763-519-0634 Fax: 763-519-0636 | |
Mr. Bradley Daniel Chmielewski, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2800 Campus Dr Ste 10, Plymouth, MN 55441 Phone: 763-559-2171 | |
Daniela T Ouzounova, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2855 Campus Dr, Ste. 400, Plymouth, MN 55441 Phone: 763-577-7400 | |
Stephanie Norris, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3007 Harbor Ln N, Plymouth, MN 55447 Phone: 952-993-8900 | |
Dr. Daniel Mark Van Handel, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 15700 37th Ave N Ste 300, Plymouth, MN 55446 Phone: 612-871-1145 Fax: 612-870-5491 |